BJUI Mini Reviews - Targeting the Receptor Activator of Nuclear Factor-κB (RANK) Ligand in Prostate Cancer Bone Metastases
This review examines emerging data indicating that bone marrow-derived RANKL might also constitute a chemoattractant factor for RANK-expressing tumour cells that is likely to contribute to the pathogenesis of bone metastases, including those arising from prostate cancer.
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2008 UroToday ® All Rights Reserved |
